PharmaLex Group expands its service portfolio with acquisition of Arlenda

The merger provides PharmaLex with a new specialised service line, further strengthening their service portfolio

As at 21st December, 2016, the PharmaLex Group, a leading specialist provider of Development Consulting & Scientific Affairs, Regulatory Affairs and Pharmacovigilance, has completed the formal merger with Arlenda.

Arlenda, a Belgium based company, specialises in strategic consulting for clinical and non-clinical statistics.

In clinical statistics, Arlenda is focused on the optimisation of clinical trial designs by simulation with a specialisation in adaptive designs. The company has a particular strength in the field of non-clinical statistics, covering research, CMC and manufacturing.

Along the value chain, it is dedicated to method development, validation, transfer and stability testing, analytical methods, bioassays, (bio)processes and stability studies. Besides the consulting activities, Arlenda commercializes software for method validation, method transfer and product stability.

Formed in 2003 around its software business, the company has become one of the fastest-growing technology companies in Belgium, adding a consulting division in 2010 and an office in the US in 2011.

“Our key focus is to solve statistical problems in our various fields of competences” explained Benoît Verjans, CEO, Arlenda.

“Recent trends show the importance of statistics in the development of robust regulatory files, therefore our statistics services offer great synergies with PharmaLex”, added Bruno Boulanger, Founder and CSO, Arlenda.

“We are delighted to welcome Arlenda to the PharmaLex Group. With increasing pressure on clients to provide quality data, we believe this addition will enable us to further strengthen our service portfolio and provide a service specifically focused on compliance" explained Dr. Thomas Dobmeyer, CEO PharmaLex.

“Our priority is to provide a high quality services to our clients. With the addition of Arlenda, we have added a specialist service which supports our wider goal of providing confidence beyond compliance” added Dr. Tilo Netzer, CEO PharmaLex.

The PharmaLex Group now has over 500 employees, with 22 offices in 12 countries and more than 550 satisfied clients worldwide.